This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bhadra, S.
Right arrow Articles by Dudley, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bhadra, S.
Right arrow Articles by Dudley, J. P.

 Previous Article  |  Next Article 

Journal of Virology, January 2009, p. 484-488, Vol. 83, No. 1
0022-538X/09/$08.00+0     doi:10.1128/JVI.01374-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

BALB/Mtv-Null Mice Responding to Strong Mouse Mammary Tumor Virus Superantigens Restrict Mammary Tumorigenesis{triangledown}

Sanchita Bhadra, Mary M. Lozano, and Jaquelin P. Dudley*

Section of Molecular Genetics and Microbiology and Institute for Cellular and Molecular Biology, The University of Texas at Austin, Austin, Texas 78712

Received 1 July 2008/ Accepted 8 October 2008


arrow
ABSTRACT
 
The absence of endogenous mouse mammary tumor viruses (MMTVs) in the congenic mouse strain, BALB/Mtv-null, restricts the early steps of exogenous C3H MMTV infection, preventing the superantigen (Sag) response and mammary tumorigenesis. Here we demonstrate that BALB/Mtv-null mice also resist tumor induction by FM MMTV, which encodes a stronger Sag compared to C3H MMTV. In contrast to infections with C3H MMTV, Mtv-null mice show FM-MMTV Sag-specific responses comparable to those observed in susceptible BALB/c mice. Neither virus shows significant replication in the spleen or mammary gland. Thus, Mtv-null mice restrict MMTV replication and mammary tumorigenesis even after a robust Sag response.


arrow
TEXT
 
Mouse mammary tumor virus (MMTV) is an oncogenic retrovirus that causes mammary carcinoma in mice after a long latency (6 to 9 months) (16). MMTV is transmitted exogenously through the milk of infected female mice to the progeny during the first 2 weeks of life, whereas the stably integrated endogenous proviruses (Mtvs) found in most laboratory mice are inherited through the germ line according to Mendelian rules (13). A majority of the endogenous proviruses are defective for replication and mammary tumorigenesis due to mutations (7, 17). However, most of these proviruses encode functional superantigens (Sags), which are expressed at the surface of antigen-presenting cells in association with major histocompatibility complex class II molecules (4, 6, 11). Sag presentation induces peripheral or intrathymic clonal deletion of most Sag-reactive T cells, resulting in an altered mouse T-cell repertoire (3, 18). Strong Sags, e.g., Mtv7, induce proliferation of cognate T cells prior to clonal deletion (20), whereas weak Sags, e.g., C3H or GR Sag, fail to induce proliferation of reactive T cells or expression of interleukin-2 receptors (15). C3H MMTV infection also has been shown to induce expression of endogenous Mtv sag gene expression (21).

Our previous work demonstrated that endogenous Mtvs play a critical role in determining susceptibility to multiple pathogens in BALB/c mice (5). BALB/c mice harbor endogenous Mtv6, Mtv8, and Mtv9 on chromosomes 16, 6, and 12, respectively (13), and are susceptible to tumorigenesis by exogenous C3H MMTV, as well as the T-cell-tropic MMTV variant, type B leukemogenic virus (TBLV). BALB/c-congenic mice lacking all endogenous Mtvs (BALB/Mtv-null) are resistant to infection and tumorigenesis by exogenous C3H MMTV (5). These mice also are resistant to TBLV, which lacks a functional sag gene (2). Interestingly, BALB/Mtv-null mice demonstrate reduced replication and mortality resulting from infection by the gram-negative bacterium, Vibrio cholerae. Genetic experiments showed that the presence of any single Mtv provirus reconstituted susceptibility to V. cholerae within 48 h, suggesting that endogenous Mtvs manipulate innate immunity (5). Since Sag is the only protein known to be encoded by all of the endogenous Mtvs of BALB/c mice, we proposed that endogenous sag genes may control immunity to multiple pathogens. In the present study, we attempted to determine whether the strong exogenous Sag encoded by the FM-MMTV strain could overcome the restriction to MMTV replication in Mtv-null animals.

BALB/Mtv-null mice respond to FM-MMTV Sag. We previously demonstrated that BALB/Mtv-null mice develop only a 10% incidence of mammary carcinomas after milk-borne infection or after intraperitoneal (i.p.) inoculation with the C3H-MMTV-based infectious clone, HYB-MTV (5, 19). C3H infection in the BALB/Mtv-null mice is impaired at an early stage since peripheral deletion of C3H Sag-reactive (CD4+ T-cell-receptor [TCR] Vβ14+) T cells is not observed (5). These results suggest that endogenous Mtv-encoded Sags are required for successful infection leading to a Sag response and tumorigenesis by C3H MMTV. The C3H MMTV strain encodes a weak Sag that causes a slow deletion of reactive T cells and causes weak cell proliferation in mixed lymphocyte reactions (1, 8).

To determine whether a stronger Sag could overcome the requirement for endogenous Mtv Sag, we inoculated BALB/Mtv-null and BALB/c mice in the footpad with mammary tumor extracts containing FM-MMTV virions. Similar to MMTV(SW), FM MMTV encodes a strong Sag that induces a three- to fourfold enlargement of draining lymph nodes and a substantial increase in the number of cognate (TCR Vβ8.2+) T cells, as well as B cells in the lymph nodes, after subcutaneous (s.c.) virus inoculation (12, 22). In contrast, the weak C3H-MMTV Sag causes only a marginal increase in reactive TCR Vβ14-expressing T cells and B cells in the draining lymph nodes (12). Single-cell suspensions were prepared from the draining popliteal lymph nodes harvested from FM-MMTV-treated or -untreated mice at 4 days postinoculation. The cells were surface stained with antibodies against CD4 and TCR Vβ8. Interestingly, the BALB/Mtv-null mice responded to the FM-MMTV Sag at levels similar to those observed in BALB/c mice. A twofold increase was observed in the proportion of CD4+ TCR Vβ8+ T cells in the draining lymph nodes of FM-MMTV-infected BALB/Mtv-null and BALB/c mice compared to uninfected mice (Fig. 1). Thus, FM MMTV stimulates the initial stages of viral replication to give a similar Sag response in both mouse strains, suggesting that endogenous Mtvs are not required for the initial infection by exogenous MMTVs encoding strong Sags.


Figure 1
View larger version (16K):
[in this window]
[in a new window]

 
FIG. 1. BALB/Mtv-null mice show T-cell proliferation specific to FM-MMTV Sag following footpad inoculation. Adult BALB/Mtv-null and BALB/c mice were inoculated in their left hind footpads with 50 µl of extracts (1:100 dilution) prepared from FM-MMTV-induced mammary tumors (kindly provided by Susan Ross). At 4 days postinfection, the draining popliteal lymph nodes were harvested from both infected and uninfected mice. Single cell suspensions were prepared from the lymph nodes and surface stained with phycoerythrin (PE)-labeled antibodies specific for mouse CD4 and fluorescein isothiocyanate (FITC)-labeled antibodies specific for mouse TCR Vβ8. The cells were analyzed on a FACSCalibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ) using CELLQuest software. The percentage of TCR Vβ8+ T cells in the gated CD4+ T-cell population was calculated. Three infected animals of each strain were used for the analysis. The mean percentage (± the standard deviation) of CD4+ TCR Vβ8+ T cells in each group is shown. The standard deviation is not shown on the control data because only one animal was used. However, the proportions of CD4+ TCR Vβ8+ T cells observed in the control BALB/c and Mtv-null lymph node populations (18 and 13%, respectively) are comparable to the proportions of these cells in the peripheral blood that has been analyzed from multiple animals of both strains (see Fig. 2A and B).

Since C3H MMTV generates only a negligible increase in reactive TCR Vβ14-expressing T cells in the draining lymph nodes of BALB/c mice (8, 12), a long-term infection assay was performed to compare infectivity of the two viral strains. BALB/c and BALB/Mtv-null mice were injected s.c. and i.p. with mammary tumor extracts containing FM MMTV. Peripheral blood lymphocytes were prepared from age-matched uninfected mice and FM-MMTV-infected mice at 1.5 and 6 months postinfection. These cells were dually stained with antibodies against CD4 and either TCR Vβ8 or Vβ3 and analyzed by flow cytometry for Sag-mediated peripheral deletion of cognate CD4+ Vβ8+ T cells. As observed in the footpad assay, the magnitude and kinetics of the FM-MMTV Sag response in Mtv-null mice were very similar to those observed in the BALB/c strain. Infected BALB/c and Mtv-null mice demonstrated ca. 50% peripheral deletion of FM-MMTV Sag-reactive CD4+ Vβ8+ T cells within 1.5 months postinfection (Fig. 2A). The deletion of FM-MMTV Sag-reactive T cells was maintained in the Mtv-null mice even at 6 months postinfection (Fig. 2B). No deletion was observed in the Sag nonreactive CD4+ Vβ3+ T-cell subset, confirming the specificity of the response to FM-MMTV Sag (Fig. 2B). This result suggests that an MMTV strain encoding a strong Sag can overcome the need for endogenous Mtvs in establishing the initial infection, leading to a robust response to the exogenous Sag. This observation contrasts with our previous results using C3H MMTV, which encodes a weak Sag and is restricted at an earlier stage in the BALB/Mtv-null mice, preventing a Sag response.


Figure 2
View larger version (46K):
[in this window]
[in a new window]

 
FIG. 2. FM-MMTV infection induces peripheral deletion of FM Sag-reactive T cells but not detectable virus expression in spleens, salivary glands, or mammary glands. Adult BALB/c and BALB/Mtv-null mice were inoculated s.c. and i.p. with 250 µl (BALB/c) or 300 µl (Mtv-null) of extracts (1:100 dilution) prepared from FM MMTV-induced mammary tumors. Peripheral blood lymphocytes were prepared from infected and age-matched uninfected animals. Sag-specific T-cell deletion in BALB/c and Mtv-null mice was analyzed at 1.5 (A) and 6 (B) months postinfection. Three animals of each strain were used as uninfected controls, while five to six infected Mtv-null and two infected BALB/c mice were used for the analysis. The cells were dually labeled with PE-conjugated antibodies specific for mouse CD4 and FITC-conjugated antibodies specific for mouse TCR Vβ8 (FM-MMTV Sag-reactive) or TCR Vβ3 (FM-MMTV Sag nonreactive), followed by analysis on a FACSCalibur using CELLQuest software. The mean percentage (± the standard deviation) of TCR Vβ8+ or Vβ3+ T cells in the gated CD4+ T-cell population was calculated. The Sag-mediated deletion of the CD4+ TCR Vβ8+ T cells in the infected animals was statistically significant as determined by a two-tailed t test (P < 0.05). (C) RT-PCR analysis from tissues or tumors obtained from FM-MMTV-infected BALB/c and Mtv-null mice. Equal amounts of RNA (treated with DNase I) were used for reverse transcription, followed by 40 cycles of PCR using FM-MMTV-specific primers (upper panel). The same cDNA preparations also were used for PCR with primers specific for gapdh (lower panel). The results from multiple animals are shown. RNAs were derived from the following sources: mammary glands (MG), spleens (SP), mammary tumors (MT), or salivary glands (SG) of BALB/c (B) or BALB/Mtv-null (N) mice. Infection with FM MMTV is indicated by a plus sign. The results from RT-PCRs shown in lanes 5, 11, 17, 20, and 24 were obtained using RNA from tissues of mice injected with both FM MMTV and TBLV. Control reactions without added reverse transcriptase gave no products (data not shown). RT-PCRs were analyzed on 1.5% agarose gels and stained with ethidium bromide. The positions of molecular mass markers (M) are shown. The arrow indicates the position of the expected 402-bp product using the FM-MMTV-specific primers within the MMTV long terminal repeat.

BALB/Mtv-null mice are resistant to FM-MMTV-induced mammary tumorigenesis. BALB/c mice inoculated with FM MMTV develop a 100% incidence of mammary carcinomas within ~8 months of infection (Table 1). Unexpectedly, despite a strong FM-MMTV Sag response, Mtv-null mice remained highly resistant to FM-MMTV-induced mammary tumors. Reactivity to FM-MMTV Sag also did not facilitate TBLV-induced lymphomagenesis in Mtv-null mice coinfected with FM MMTV and the TBLV molecular clone (HYB-TBLV) (14) expressed from stably transfected Jurkat T cells (Table 1). These mice demonstrated peripheral deletion of FM-MMTV Sag-reactive CD4+ Vβ8+ T cells (data not shown) but failed to develop TBLV-induced lymphomas. The tumorigenicity of HYB-TBLV was verified by infection of adult BALB/c mice, which developed a 75% incidence of TBLV-induced thymic T-cell lymphomas within 4 months (Table 1).


View this table:
[in this window]
[in a new window]

 
TABLE 1. Incidence and latency of tumors in virus-infected mice

To confirm that infection was restricted in the Mtv-null mice, RNA was extracted as previously described (5) from multiple organs of BALB/c and Mtv-null animals infected with FM MMTV and subjected to reverse transcription-PCR (RT-PCR) (Fig. 2C). Mammary glands (lane 1), spleens (lanes 7, 18, and 19), and salivary glands (lanes 22 and 23) from FM-MMTV-infected BALB/c animals all showed the 402-bp fragment expected from transcription of integrated FM-MMTV proviruses, a finding consistent with the spread of the viral infection. However, Mtv-null mice lacked detectable FM-MMTV transcription in these same tissues (lanes 3, 4, 5, 9, 10, 11, 20, 21, 24, and 25) even after multiple pregnancies and lactations, which should amplify virus expression from hormone response elements in the LTR. In addition, mammary tumors arising in FM-MMTV BALB/c mice had easily detectable viral transcripts (lanes 14 to 16), whereas the single mammary tumor arising in FM-MMTV-infected Mtv-null mice did not (lane 17). The quality of all cDNA preparations was verified using primers specific for glyceraldehyde-3-phosphate dehydrogenase (gapdh). Together, these results suggest that Sag-specific deletion in FM-MMTV-infected Mtv-null mice does not lead to significant infection of B and T cells or other cell types.

Not surprisingly, milk-borne transmission of FM MMTV from infected Mtv-null females to their offspring was not observed, as demonstrated by the lack of Sag-specific T-cell deletion (Fig. 3) or mammary tumor development (Table 1). In contrast, the progeny of FM-MMTV-infected BALB/c females developed a 100% incidence of mammary tumors, indicating successful milk-borne transmission in susceptible mice (Table 1). Our previous experiments revealed a strong correlation between the extent of Sag-mediated deletion of cognate T cells and MMTV tumorigenicity (5). However, the BALB/Mtv-null mice appear to restrict FM MMTV after a Sag-mediated T-cell response, thus preventing viral tumorigenesis, as well as milk-borne transmission.


Figure 3
View larger version (17K):
[in this window]
[in a new window]

 
FIG. 3. Milk-borne transmission of FM MMTV does not occur in BALB/Mtv-null mice. Peripheral blood lymphocytes from three age-matched uninfected control mice and eight 3-month-old offspring of FM MMTV-infected Mtv-null mice were dually labeled with PE-conjugated antibodies specific for mouse CD4 and FITC-conjugated antibodies specific for mouse TCR Vβ8 (FM Sag-reactive) or TCR Vβ3 (FM Sag nonreactive), followed by analysis on a FACSCalibur using CELLQuest software. The mean percentage (± the standard deviation) of TCR Vβ8+ or Vβ3+ T cells in the gated CD4+ T-cell population was calculated.

Our results suggest that the absence of endogenous Mtvs creates different blocks to the replication and tumorigenicity of exogenous MMTV in BALB/Mtv-null mice. If the exogenous MMTV encodes a weak Sag, e.g., C3H MMTV, endogenous Sags are essential during the early stages of infection, leading to exogenous Sag presentation and cognate T-cell deletion (5). C3H MMTV infection is known to cause a rapid induction of endogenous Mtv Sag expression in gut-associated lymphoid tissue, spleen, and thymus as early as 24 h postinfection in BALB/c mice (21). In contrast, the endogenous Mtv Sag expression remains low to undetectable in infected C57BL/6 mice, which are relatively resistant to C3H MMTV. The increased endogenous Mtv Sag expression could be an indirect effect of cellular activation after exogenous MMTV infection (21). In addition, increased amounts of endogenous Sag might be indicative of their critical role in establishing infection by C3H MMTV in BALB/c mice.

Exogenous viral strains expressing strong Sags, such as FM MMTV, also can establish the first stages of infection (presumably the infection of dendritic cells) (9) in the absence of endogenous Mtvs. BALB/Mtv-null mice show a robust response to FM-MMTV Sag, indicating that the initial steps of viral infection and Sag expression occur to the same extent as in the BALB/c mice. The ability of FM-MMTV Sag to overcome the requirement for endogenous Mtvs in establishing a robust viral infection might be due to its property of inducing proliferation of cognate T cells prior to clonal deletion. However, this T-cell response does not lead to significant MMTV replication in B or T cells or the spread of virus to the mammary gland. On the other hand, C3H-MMTV Sag, which lacks the ability to induce cognate T-cell proliferation, may depend on endogenous Mtvs to achieve viral amplification in the earliest stages of infection that would eventually lead to Sag-specific T-cell deletion and virus-induced mammary tumorigenesis. Nevertheless, we cannot rule out that FM and C3H MMTV have essentially the same block to infection. Both viruses may cause a low-level infection and presentation of their respective Sag proteins in the same cell type, but only the stronger Sag may function.

Despite the establishment of infection and a robust FM-MMTV Sag response, the Mtv-null animals remain highly resistant to FM-MMTV-induced mammary tumorigenesis (Table 1), lack detectable proviral transcription in mammary glands (Fig. 2C), and also fail to transmit the virus in their milk (Fig. 3). This observation suggests that the absence of endogenous Mtvs results in a later block to replication of viruses encoding strong Sags. Our experiments indicate that MMTV infection is not established in B and T cells, which results in the lack of transmission to the mammary epithelial cells. Transfer of infected splenocytes from C3H MMTV-infected BALB/c mice into BALB/Mtv-null mice also failed to establish MMTV infection and tumorigenesis in the Mtv-null recipients (data not shown). The restriction of MMTV-induced tumorigenesis may also result from a cell-mediated immune response against MMTV-infected cells. Our previous results show that, unlike BALB/c mice, Mtv-null animals completely restrict the outgrowth of BALB/c B-cell lymphomas (A20) stably expressing HYB-MTV, while A20 cells lacking HYB-MTV readily form tumors in both mouse strains (5). Another possibility is that endogenous Mtv-encoded Sags activate NK cells and cytokines that are critical for the growth of exogenous MMTV-induced tumors (10), which is consistent with our previous hypothesis that endogenous Mtvs alter innate immunity (5). In summary, our results demonstrate that Mtvs play a crucial role at early stages during the infection cycle of exogenous MMTVs leading to tumorigenesis and milk-borne viral transmission.


arrow
ACKNOWLEDGMENTS
 
We acknowledge helpful suggestions from the Dudley lab.

This study was supported by National Institutes of Health grant R01 CA116813.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Section of Molecular Genetics and Microbiology, The University of Texas at Austin, One University Station, A5000, 2506 Speedway, NMS 2.104, Austin, TX 78712-0162. Phone: (512) 471-8415. Fax: (512) 471-7088. E-mail: jdudley{at}uts.cc.utexas.edu Back

{triangledown} Published ahead of print on 15 October 2008. Back


arrow
REFERENCES
 
    1
  1. Acha-Orbea, H., A. N. Shakhov, L. Scarpellino, E. Kolb, V. Muller, A. Vessaz-Shaw, R. Fuchs, K. Blochlinger, P. Rollini, J. Billotte, M. Sarafidou, H. R. MacDonald, and H. Diggelmann. 1991. Clonal deletion of V β 14-bearing T cells in mice transgenic for mammary tumour virus. Nature 350:207-211.
  2. 2
  3. Ball, J. K., H. Diggelmann, G. A. Dekaban, G. F. Grossi, R. Semmler, P. A. Waight, and R. F. Fletcher. 1988. Alterations in the U3 region of the long terminal repeat of an infectious thymotropic type B retrovirus. J. Virol. 62:2985-2993.[Abstract/Free Full Text]
  4. 3
  5. Barnett, A., F. Mustafa, T. J. Wrona, M. Lozano, and J. P. Dudley. 1999. Expression of mouse mammary tumor virus superantigen mRNA in the thymus correlates with kinetics of self-reactive T-cell loss. J. Virol. 73:6634-6645.[Abstract/Free Full Text]
  6. 4
  7. Beutner, U., B. McLellan, E. Kraus, and B. T. Huber. 1996. Lack of MMTV superantigen presentation in MHC class II-deficient mice. Cell. Immunol. 168:141-147.[CrossRef][Medline]
  8. 5
  9. Bhadra, S., M. M. Lozano, S. M. Payne, and J. P. Dudley. 2006. Endogenous MMTV proviruses induce susceptibility to both viral and bacterial pathogens. PLoS Pathog. 2:e128.[CrossRef][Medline]
  10. 6
  11. Blackman, M. A., F. E. Lund, S. Surman, R. B. Corley, and D. L. Woodland. 1992. Major histocompatibility complex-restricted recognition of retroviral superantigens by V β 17+ T cells. J. Exp. Med. 176:275-280.[Abstract/Free Full Text]
  12. 7
  13. Cho, K., D. A. Ferrick, and D. W. Morris. 1995. Structure and biological activity of the subgenomic Mtv-6 endogenous provirus. Virology 206:395-402.[CrossRef][Medline]
  14. 8
  15. Choi, Y., J. W. Kappler, and P. Marrack. 1991. A superantigen encoded in the open reading frame of the 3' long terminal repeat of mouse mammary tumour virus. Nature 350:203-207.
  16. 9
  17. Courreges, M. C., D. Burzyn, I. Nepomnaschy, I. Piazzon, and S. R. Ross. 2007. Critical role for dendritic cells in mouse mammary tumor virus in in vivo infection. J. Virol. 81:3769-3777.[Abstract/Free Full Text]
  18. 10
  19. Gill, R., H. Wang, H. Bluethmann, A. Iglesias, and W. Z. Wei. 1994. Activation of natural killer cells by mouse mammary tumor virus C4 in BALB/c and T-cell receptor V β 2-transgenic mice. Cancer Res. 54:1529-1535.[Abstract/Free Full Text]
  20. 11
  21. Grigg, M. E., C. W. McMahon, S. Morkowski, A. Y. Rudensky, and A. M. Pullen. 1998. Mtv-1 superantigen trafficks independently of major histocompatibility complex class II directly to the B-cell surface by the exocytic pathway. J. Virol. 72:2577-2588.[Abstract/Free Full Text]
  22. 12
  23. Held, W., A. N. Shakhov, G. Waanders, L. Scarpellino, R. Luethy, J. P. Kraehenbuhl, H. R. MacDonald, and H. Acha-Orbea. 1992. An exogenous mouse mammary tumor virus with properties of Mls-1a (Mtv-7). J. Exp. Med. 175:1623-1633.[Abstract/Free Full Text]
  24. 13
  25. Kozak, C., G. Peters, R. Pauley, V. Morris, R. Michalides, J. Dudley, M. Green, M. Davisson, O. Prakash, and A. Vaidya. 1987. A standardized nomenclature for endogenous mouse mammary tumor viruses. J. Virol. 61:1651-1654.[Abstract/Free Full Text]
  26. 14
  27. Mustafa, F., S. Bhadra, D. Johnston, M. Lozano, and J. P. Dudley. 2003. The type B leukemogenic virus truncated superantigen is dispensable for T-cell lymphomagenesis. J. Virol. 77:3866-3870.[Abstract/Free Full Text]
  28. 15
  29. Nakano, H., T. Yoshimoto, H. Nariuchi, T. Kakiuchi, and A. Matsuzawa. 1996. Deletion of peripheral V β 14+ T cells by Mtv-2-encoded viral superantigen preceded by blastogenesis and DNA synthesis but not by specific expansion. Cell. Immunol. 168:281-290.[CrossRef][Medline]
  30. 16
  31. Ross, S. R. 2000. Using genetics to probe host-virus interactions; the mouse mammary tumor virus model. Microbes Infect. 2:1215-1223.[CrossRef][Medline]
  32. 17
  33. Salmons, B., G. Knedlitschek, N. Kennedy, B. Groner, and H. Ponta. 1986. The endogenous mouse mammary tumour virus locus Mtv-8 contains a defective envelope gene. Virus Res. 4:377-389.[CrossRef][Medline]
  34. 18
  35. Scherer, M. T., L. Ignatowicz, A. Pullen, J. Kappler, and P. Marrack. 1995. The use of mammary tumor virus (Mtv)-negative and single-Mtv mice to evaluate the effects of endogenous viral superantigens on the T-cell repertoire. J. Exp. Med. 182:1493-1504.[Abstract/Free Full Text]
  36. 19
  37. Shackleford, G. M., and H. E. Varmus. 1988. Construction of a clonable, infectious, and tumorigenic mouse mammary tumor virus provirus and a derivative genetic vector. Proc. Natl. Acad. Sci. USA 85:9655-9659.[Abstract/Free Full Text]
  38. 20
  39. Waanders, G. A., A. N. Shakhov, W. Held, O. Karapetian, H. Acha-Orbea, and H. R. MacDonald. 1993. Peripheral T-cell activation and deletion induced by transfer of lymphocyte subsets expressing endogenous or exogenous mouse mammary tumor virus. J. Exp. Med. 177:1359-1366.[Abstract/Free Full Text]
  40. 21
  41. Xu, L., T. J. Wrona, and J. P. Dudley. 1996. Exogenous mouse mammary tumor virus (MMTV) infection induces endogenous MMTV sag expression. Virology 215:113-123.[CrossRef][Medline]
  42. 22
  43. Yoshimoto, T., H. Nagase, H. Nakano, A. Matsuzawa, and H. Nariuchi. 1994. A V β 8.2-specific superantigen from exogenous mouse mammary tumor virus carried by FM mice. Eur. J. Immunol. 24:1612-1619.[Medline]


Journal of Virology, January 2009, p. 484-488, Vol. 83, No. 1
0022-538X/09/$08.00+0     doi:10.1128/JVI.01374-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Okeoma, C. M., Petersen, J., Ross, S. R. (2009). Expression of Murine APOBEC3 Alleles in Different Mouse Strains and Their Effect on Mouse Mammary Tumor Virus Infection. J. Virol. 83: 3029-3038 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bhadra, S.
Right arrow Articles by Dudley, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bhadra, S.
Right arrow Articles by Dudley, J. P.